Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033
Jazz Pharmaceuticals entered into Amendment No. 4 to its Credit Agreement to extend and reprice its U.S. dollar term loan, converting Tranche B-2 into a new $1.895 billion Tranche B-3. The maturity moves to May 5, 2033, and margins drop by 50 bps to 1.75% over Term SOFR (0.75% over prime), with a 0…